Cargando…

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with the risk of developing immune-related adverse events (irAEs). Although ICI-associated pancreatic adverse events (AEs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yue, Fang, Yisheng, Wu, Jianhua, Huang, Genjie, Bin, Jianping, Liao, Yulin, Shi, Min, Liao, Wangjun, Huang, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012537/ https://www.ncbi.nlm.nih.gov/pubmed/35431928 http://dx.doi.org/10.3389/fphar.2022.817662

Ejemplares similares

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
por: Guo, Qian, et al.
Publicado: (2023)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis
por: Wang, Xuyan, et al.
Publicado: (2023)

Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer
por: Fang, Yisheng, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
por: Huang, Jing, et al.
Publicado: (2023)

Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
por: Lombardi, Niccolò, et al.
Publicado: (2019)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis
por: Lu, Wenchao, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization’s Reporting? A Pharmacovigilance Study in Southern Italy
por: Scavone, Cristina, et al.
Publicado: (2018)

Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study)
por: Lombardi, Niccolò, et al.
Publicado: (2020)

Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate
por: Chen, Xiaoyi, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome
por: Zheng, Cankun, et al.
Publicado: (2022)

Subsite‐specific metastatic organotropism and risk in gastric cancer: A population‐based cohort study of the US SEER database and a Chinese single‐institutional registry
por: Wang, Ling, et al.
Publicado: (2023)

Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
por: Zheng, Yannan, et al.
Publicado: (2023)

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates
por: Güner, Müberra Devrim, et al.
Publicado: (2019)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

An update on the Pharmacovigilance Programme of India
por: Lihite, Ratan J., et al.
Publicado: (2015)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

A National Survey of Community Pharmacists’ Viewpoints About Pharmacovigilance and Adverse Drug Reaction Reporting in Saudi Arabia
por: Alsheikh, Mona Y., et al.
Publicado: (2022)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
por: Tang, Shu, et al.
Publicado: (2022)

Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β(2)‐AR/MACC1 axis
por: Pan, Changqie, et al.
Publicado: (2021)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials
por: Zhang, Weidong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2u4t2dl10pom8q4h04f4n8ese0